Establishment of PDX-derived oral cancer cell lines and utility of anti-HER2 antibody therapy

被引：0
|
作者：
Seki, Yuki [1 ]
Kariya, Ryusyo [2 ]
Yoshida, Ryoji [3 ]
Kawahara, Kenta [3 ]
Hirayama, Masatoshi [3 ]
Nakamoto, Masafumi [3 ]
Hirosue, Akiyuki [3 ]
Okada, Seiji [2 ]
Nakayama, Hideki [3 ]
机构：
[1] Kumamoto Univ, Grad Sch Med Sci, Kumamoto, Japan
[2] Kumamoto Univ, Div Hematopoiesis Joint Res Ctr Human Retrovirus, Kumamoto, Japan
[3] Kumamoto Univ, Fac Life Sci, Dept Oral & Maxillofac Surg, Kumamoto, Japan
来源：
CANCER SCIENCE | 2025年 / 116卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
P-2238
引用
收藏
页码：990 / 990
页数：1
相关论文
共 50 条
  • [31] Predicting gastric cancer response to anti-HER2 therapy or anti-HER2 combined immunotherapy based on multi-modal data
    Chen, Zifan
    Chen, Yang
    Sun, Yu
    Tang, Lei
    Zhang, Li
    Hu, Yajie
    He, Meng
    Li, Zhiwei
    Cheng, Siyuan
    Yuan, Jiajia
    Wang, Zhenghang
    Wang, Yakun
    Zhao, Jie
    Gong, Jifang
    Zhao, Liying
    Cao, Baoshan
    Li, Guoxin
    Zhang, Xiaotian
    Dong, Bin
    Shen, Lin
    SIGNAL TRANSDUCTION AND TARGETED THERAPY, 2024, 9 (01)
  • [32] Long-term responders to single-agent margetuximab, an Fc-modified anti-HER2 monoclonal antibody, in metastatic HER2+breast cancer patients with prior anti-HER2 therapy
    Im, S-A
    Bang, Y-J
    Oh, D-Y
    Giaccone, G.
    Bauer, T.
    Nordstrom, J.
    Li, H.
    Moore, P.
    Hong, S.
    Baughman, J.
    Rock, E.
    Burris, H.
    CANCER RESEARCH, 2019, 79 (04)
  • [33] Targeted Anti-HER2 Cancer Therapy in Elderly Women Diagnosed with Breast Cancer
    Molina-Garrido, M. J.
    Guillen-Ponce, C.
    Mora-Rufete, A.
    ANTI-CANCER AGENTS IN MEDICINAL CHEMISTRY, 2014, 14 (05) : 639 - 645
  • [34] Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
    G L Banna
    S M L Aversa
    G Crivellari
    C Ghiotto
    V Chiarion-Sileni
    S Monfardini
    British Journal of Cancer, 2006, 94 : 1550 - 1552
  • [35] Administration of anti-HER2 antibody after nonmyeloablative allogeneic stem cell transplantation in metastatic breast cancer
    Banna, G. L.
    Aversa, S. M. L.
    Crivellari, G.
    Ghiotto, C.
    Chiarion-Sileni, V.
    Monfardini, S.
    BRITISH JOURNAL OF CANCER, 2006, 94 (10) : 1550 - 1552
  • [36] Is there a case for anti-HER2 therapy without chemotherapy in early breast cancer?
    Constantinidou, Anastasia
    Smith, Ian
    BREAST, 2011, 20 : S158 - S161
  • [37] Takotsubo Cardiomyopathy During Anti-HER2 Therapy for Metastatic Breast Cancer
    Lees, Caitlin
    Yazdan-Ashoori, Payam
    Jerzak, Katarzyna J.
    Gandhi, Sonal
    ONCOLOGIST, 2019, 24 (02): : E80 - E82
  • [38] Lung toxicity induced by anti-HER2 antibody - drug conjugates for breast cancer
    Chai, Mengting
    Li, Li
    Wu, Huachao
    Liu, Yue
    Yi, Zongbi
    Yu, Haijun
    CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2024, 195
  • [39] Development of an anti-HER2 antibody-NKG2D ligand fusion protein for breast cancer therapy.
    Shin, S-U
    Cho, H-M
    Tolba, K.
    Calfa, C.
    Shin, S. J.
    Zhang, Y.
    Rosenblatt, J. D.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S30 - S30
  • [40] Development of paclitaxel-loaded liposomal systems with anti-her2 antibody for targeted therapy
    Buyukkoroglu, Gulay
    Senel, Behiye
    Basaran, Ebru
    Gezgin, Seval
    TROPICAL JOURNAL OF PHARMACEUTICAL RESEARCH, 2016, 15 (05) : 895 - 903
12345